Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. (Articolo in rivista) (literal)

Anno

• 1994-01-01T00:00:00+01:00 (literal)

Alternative label

• Rasi G*, Silecchia G, Sinibaldi-Vallebona P*, Spaziani E, Pierimarchi P*, Sivilia M, Tremiterra S, Garaci E. (1994)
  Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
  in International journal of cancer (Online)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Rasi G*, Silecchia G, Sinibaldi-Vallebona P*, Spaziani E, Pierimarchi P*, Sivilia M, Tremiterra S, Garaci E. (literal)

Pagina inizio

• 701 (literal)

Pagina fine

• 705 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 57 (literal)

Rivista

• International journal of cancer (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• *Istituto di Medicina Sperimentale, Consiglio Nazionale delle Ricerche (CNR), Rome, Italy. (literal)

Titolo

• Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. (literal)

Abstract

• We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats. The presence of liver metastases was checked by laparotomy 14 days after tumor-cell injection. Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2. 5-FU was administered i.v. as a continuous infusion for 7 days by an osmotic device implanted surgically. T alpha 1 and IL-2 were administered for 4 days and repeated after 11 days. Combined chemo-immunotherapy was shown both to significantly reduce the growth of liver metastases and to prevent extra-hepatic spread. 5-FU/T alpha 1/IL-2 also improved survival rate. Combined immunotherapy after 5-FU restored NK activity of the peripheral-blood-mononuclear-cell (PBMC) in tumor and/or 5-FU immunodepressed rats and enhanced PBMC cytotoxic activity against the DHD/K12 autologous cell line. This model was devised to mimic the clinical situation of unresectable liver metastases. (literal)

Prodotto di

• Patologie infettive, infiammatorie e degenerative (ME.P04.005.001) (Modulo)

Autore CNR

• PAOLA SINIBALDI VALLEBONA (Persona)
• PASQUALE PIERIMARCHI (Unità di personale interno)
• GUIDO RASI (Unità di personale esterno)

Incoming links:

Autore CNR di

• PASQUALE PIERIMARCHI (Unità di personale interno)
• PAOLA SINIBALDI VALLEBONA (Persona)
• GUIDO RASI (Unità di personale esterno)

Prodotto

• Patologie infettive, infiammatorie e degenerative (ME.P04.005.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• International journal of cancer (Rivista)